The size of the Cancer Monoclonal Antibodies Market in North America was worth USD 10.64 billion in 2022. This value is further expected to grow and worth USD 17.53 billion by the end of 2027, registering a CAGR of 10.5% from 2022 to 2027.
The market is mainly driven by the increasing number of patients suffering from different types of cancer. Growing demand to improve the quality of treatment procedures is surging the growth rate of the market. The rise in the revenue in both developed and developing countries are greatly influencing the demand for the cancer monoclonal antibodies market in North America. Growing support from the government and non-government organizations through investments in the construction o hospitals is propelling this market's demand. Also, increasing the scale of hospitals with the latest equipment is leveraging the growth of the market.
Growing popularity in manufacturing new products with the latest technology is creating growth opportunities for the market. Increasing prevalence to promote the wellbeing of the patient after treatment is also likely to outshine the market demand. Escalating healthcare expenditure, especially in urban areas, is boosting up the growth rate of North American cancer monoclonal antibodies.
However, lack of proper knowledge over the availability of different treatment procedures due to less training programs is slightly restricting the demand of the market. Fluctuations in the availability of raw materials are hindering the growth rate of this market in North America. Rapid changes in economic strategies are also impacting negatively on the growth of the cancer monoclonal antibodies market. Increasing prices of final products remain a challenging factor for the market.
This research report on the North America Cancer Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories:
By Application:
By Type:
By Conjugated Cancer Therapies:
By Country:
Regionally, North America is holding with the highest shares of the market, and the USA is the one ruling with dominant shares of the market in this region. Rising capital income is one of the most common factors propelling the growth of the market. Canada and Mexico are next to the USA in leading dominant shares of the market. Increasing investments in the development of new techniques in cancer treatment procedures elevates the growth rate of the cancer monoclonal antibodies market in North America.
Promising companies operating in the North American Cancer Monoclonal Antibodies Market profiled in this report are Amgen, Genmab, Briston Myers Squibb, GlaxoSmithKline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis, and Spectrum Pharmaceuticals.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Application
5.1.1 Liver
5.1.2 Breast
5.1.3 Brain
5.1.4 Blood
5.1.5 Hodgkins and Non-Hodgkins lymphoma
5.1.6 Colorectal
5.1.7 Leukaemia
5.1.8 Others
5.2 By Type
5.2.1 Murine Antibodies
5.2.2 Chimeric and Humanised Antibodies
5.2.3 Fully Humanized Antibodies
5.3 Conjugate Cancer Therapies
5.3.1 Immunoliposome
5.3.2 Radioimmunotherapy
5.3.3 ADEPT
5.3.4 Immunocytokines
5.3.5 Others
6.1 Introduction
6.2 United States
6.3 Canada
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Amgen
8.3 Genmab
8.4 Glaxosmithkline
8.5 Bristol Meyer Squibb
8.6 Eli Lilly
8.7 Immunogen
8.8 Novartis
8.9 Seattle Genetics
8.10 Spectrum Pharmaceuticals
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.